Eos Energy Enterprises Inc vs Novavax Inc — how do they compare? Eos Energy Enterprises Inc trades at $4.05 (market cap $1.55B), while Novavax Inc trades at $8.22 (market cap $1.39B). The key difference: Eos Energy Enterprises Inc and Novavax Inc are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.
| EOSE | NVAX | |
|---|---|---|
Market Cap | $1.55B | $1.39B |
Sector | Energy | Health |
52-Week High | $19.19 | $11.19 |
52-Week Low | $4.29 | $6.22 |
Enterprise Value | $1.79B | $890.94M |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.21, down 1.86% on the day, amid a bearish technical signal. The company reported a net loss of $969.65 million on $114.20 million revenue in 2025, with negative gross and net profit margins, but revenue growth is accelerating into 2026. Recent news highlights record quarterly revenue expectations and a $125 million investment for Frontier Power USA, signaling strong commercial momentum.
The outlook is mixed: accelerating revenue and a growing project backlog offer upside potential, but persistent losses and high debt-to-asset ratio of 91.87% pose significant financial risks. Analyst consensus is a 'Hold' with a $9.00 price target, reflecting cautious optimism balanced by execution concerns in the competitive energy storage market.
Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.
The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →